

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/990,405	11/21/2001		Alan L. Mueller	50877.0030	4028
26582	7590	02/27/2006		EXAM	INER
HOLLAND	& HAR	T, LLP	KWON, BRIAN YONG S		
P.O BOX 87				- P.W. I.D. U.W.	DARED MUMBER
DENVER, C	CO 8020	1	ART UNIT	PAPER NUMBER	
				1614	

DATE MAILED: 02/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/990,405	MUELLER ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Brian S. Kwon	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - Exte after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR I MAILING DATE OF THIS COMMUNICAT nsions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communica e period for reply specified above is less than thirty (30) day period for reply is specified above, the maximum statutory are to reply within the set or extended period for reply will, b reply received by the Office later than three months after the d patent term adjustment. See 37 CFR 1.704(b).	TION. CFR 1.136(a). In no event, however, may a tion. s, a reply within the statutory minimum of thir period will apply and will expire SIX (6) MOI y statute, cause the application to become A	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed or	05 December 2005.					
2a) <u></u>	This action is <b>FINAL</b> . 2b)	This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 5,6 and 21-29 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  Claim(s) is/are allowed.  Claim(s) 5,6 and 21-29 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
9)	The specification is objected to by the Ex	aminer.					
10)[	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority (	under 35 U.S.C. § 119						
a)	Acknowledgment is made of a claim for for All b) Some * c) None of:  1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International Election for	uments have been received.  uments have been received in A e priority documents have been Bureau (PCT Rule 17.2(a)).	Application No  received in this National Stage				
	e of References Cited (PTO-892)		Summary (PTO-413)				
3) 🔲 Infon	ce of Draftsperson's Patent Drawing Review (PTO-9 mation Disclosure Statement(s) (PTO-1449 or PTO/ er No(s)/Mail Date		s)/Mail Date Informal Patent Application (PTO-152) 				

Application/Control Number: 09/990,405 Page 2

Art Unit: 1614

#### **DETAILED ACTION**

### Status of Application

1. Acknowledgement is made of applicants' filing of the instant application as a Request for Continued Examination (RCE) under 37 CFR 1.1114.

2. By Amendment filed December 05, 2005, claims 5 and 25-27 have been amended and claims 28-29 have been newly added. Claims 5-6 and 21-29 are currently pending for prosecution on the merits.

## Response to Arguments

3. Applicant's arguments with respect to claims 5-6 and 21-24 have been considered but are moot in view of the new ground(s) of rejection.

#### Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various

Application/Control Number: 09/990,405

Art Unit: 1614

claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 5-6 and 21-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mueller et al. (WO 96/40097) in view of Skolnick et al. (Pharmacopsychiatry, abstract, 1996 January, 29:1, 23-6).

Mueller discloses the claimed compounds represented by the formula, for example the compound 20 and the compound 60, as NMDA receptor antagonist that is useful for the treatment of neurological disorders including epilepsy, Alzheimer's disease, Parkinson's disease, and Huntington's disease (abstract; pages 24-25; pages 62-64; claims 1, 18, 19 and 77 and 80).

Skolnick provides links between NMDA receptor antagonist and the treatment of depression. Skolnick teaches that NMDA antagonist mimic the effects of clinically effective antidepressants in both preclinical tests predictive antidepressant action and procedures designed to model aspects of depressive symptomatology; and NMDA receptors is involved in the pathophysiology of depression (abstract).

The teaching of Mueller differs from the claimed invention in the use of the claimed compound represented by the formula, namely 3-fluoro-γ-(3-fluorophenyl)-N-methylbenzenepropanamine (compound 60), for the treatment of depression. To incorporate such teaching into the teaching of Mueller, would have been obvious in view of Skolnick who teaches nexus between NMDA receptor antagonist and the treatment of depression.

Application/Control Number: 09/990,405 Page 4

Art Unit: 1614

One having ordinary skilled in the art at the time of the invention was made would have expected as taught by Skolnick that NMDA receptor mechanism is involved in pathophysiology of depression and the downregulation of NMDA receptor by NMDA antagonist would provide clinical utility in the treatment of depression. Thus, one would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities), and pertinent to the problem

## Conclusion

5. No Claim is allowed.

which applicant concerns about. MPEP 2141.01(a).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (571) 272-0951. The fax number for this Group is (703) 872-9306.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Brian Kwon
Patent Examiner
AU 1614

Bol